SWOG clinical trial number
              SWOG-9143
          A Phase II Study of Cisplatin Preceded by a 12-hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Patients with Untreated Malignant Mesothelioma
Closed
      
  Phase
              Accrual
  
                          
      100%
      
  
    Published
      
  Abbreviated Title
              A Phase II Study of Cisplatin Preceded by a 12-hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Patients with Untreated Malignant Mesothelioma
          Activated
              08/15/1992
          Closed
              09/15/1994
          